The effects of inflammation on nutritional rehabilitation after starting antiretroviral therapy (ART) are not well understood. We assessed the relationship between inflammation and body composition among patients enrolled in the Nutritional Support for African Adults Starting Antiretroviral therapy (NUSTART) trial in Tanzania and Zambia from 2011 to 2013. SUBJECTS/METHODS: HIV-infected, ART-eligible adults with body mass index (BMI) of o 18.5 kg/m 2 enrolled in the NUSTART trial were eligible for this study. Anthropometric and body composition data were collected at recruitment and 6 and 12 weeks post ART and C-reactive protein (CRP) was measured at recruitment and 6 weeks. The relationships between CRP and body composition were assessed using multiple regression. RESULTS: Of the 1815 trial participants, 838 (46%) had baseline and 6-week CRP measurements. Median age was 36 years, 55% were females and median CD4 count was 135 cells/μl. A one-log reduction in CRP at 6 weeks was associated with increased mid-upper arm circumference (0.45 cm; 95% CI: 0.30, 0.61), calf circumference (0.38 cm; 0.23, 0.54), waist circumference (0.98 cm; 0.59, 1.37), BMI (0.37 kg/m 2 ; 0.24, 0.50) and fat-free mass (0.58 kg; 0.26, 0.91), but not with fat mass (0.09 kg; − 0.17, 0.34). Fat-free mass gains persisted at 12 weeks and were more closely associated with 6-week CRP values than with baseline values. CONCLUSIONS: Reduction in CRP shortly after ART initiation was associated with higher fat-free mass gains. Further studies are warranted to determine whether interventions to reduce systemic inflammation will enhance gains in fat-free mass.
INTRODUCTION
Infection with HIV continues to be a major public health problem in Sub-Saharan Africa. Despite efforts to promote early diagnosis and treatment initiation before the onset of advanced disease, over a third of HIV-infected patients initiate antiretroviral therapy (ART) after developing malnutrition (that is, a body mass index (BMI) of o 18.5 kg/m 2 ), and early mortality in this group is exceedingly high. 1, 2 Prior studies in Africa investigating the effects of nutritional supplementation in the early ART period have not shown a mortality benefit, and some supplements may actually produce a disproportionate increase in fat mass. 3, 4 A greater recovery of lean mass, as opposed to fat mass, during the early HIV treatment period may improve survival and reduce the long-term risk of developing chronic diseases, but factors influencing lean mass gains among malnourished adults starting ART are poorly understood. 5 Malnutrition and HIV infection are accompanied by high levels of systemic inflammation, due in part to unchecked viremia, reduced mucosal defenses and opportunistic infections. [6] [7] [8] In advanced HIV infection, an elevated rate of protein turnover and inappropriately low muscle protein synthesis prevent weight gain despite sufficient intake of calories and protein. [9] [10] [11] With the initiation of ART and suppression of viremia, systemic inflammation normalizes to varying degrees, with a concomitant reduction in resting metabolic expenditures and improved weight gain in most undernourished patients. 12, 13 However, abnormalities in factors related to body mass partitioning, such as an elevated rate of lipolysis, can persist in some patients despite viral suppression and may have effects on subsequent nutritional rehabilitation. 14 In prior studies, aggressive parenteral nutrition in critically ill patients did not markedly improve lean body mass, 15 and weight gain during treatment for pulmonary tuberculosis was primarily due to increases in adipose tissue rather than lean mass. 16 We hypothesized that a failure to normalize systemic inflammation after starting ART impairs recovery of lean mass and biases weight gain toward adipose tissue deposition. Using data from malnourished HIV-infected patients enrolled in a nutritional supplementation trial in Tanzania and Zambia, we analyzed the relationships between C-reactive protein (CRP) and fat and fat-free mass immediately before and during first 12 weeks of ART.
MATERIALS AND METHODS
This study was conducted as part of the Nutritional Support for Africans Starting Antiretroviral Therapy (NUSTART) trial (registration no. PACTR201106000300631), a randomized, double-blind, controlled trial of a lipid-based nutritional supplement (LNS; prepared by Nutriset, Malauney, France) in 1815 malnourished HIV-infected patients starting ART in Mwanza, Tanzania and Lusaka, Zambia. The study was conducted between August 2011 and December 2013. NUSTART participants were randomized to receive either the LNS alone (control arm) or fortified with additional vitamins and minerals (intervention arm; LNS-VM) in a two-stage nutritional intervention designed to mimic standard protocols for management of severe malnutrition in young children. From recruitment until 2 weeks after starting ART, participants received a low-calorie (30 g) LNS, and during weeks 2-6 of ART, participants received a high-calorie (250 g or 1400 kcal/day) LNS. Trial inclusion criteria were ≥ 18 years of age, ARTnaive except for standard regimens to prevent maternal-to-child HIV transmission, BMI o18.5 kg/m 2 and a CD4 count o350 cells/μl or World Health Organization (WHO) stage 3 or 4 disease. Self-reported pregnancy was an exclusion criterion. In a separate analysis, LNS-VM compared with LNS did not increase fat mass or fat-free mass at 12 weeks of ART.
NUSTART participants underwent detailed body composition and laboratory studies as part of an intensive visit schedule. After recruitment, patients came to the clinic weekly until the start of ART, and again at weeks 1, 2, 4, 6, 8 and 12 after starting ART. Height was measured at recruitment using a stadiometer fixed to the wall and weight at each visit using a digital balance. At recruitment, 2, 6 and 12 weeks after starting ART, patients underwent additional anthropometric evaluation. Waist, mid-upper arm, hip and calf circumferences were measured using a flexible tape, and triceps and subscapular skinfold thickness using a caliper in Lusaka only. All measurements were done in triplicate and the median value was recorded for analyses. Participants also underwent bioelectrical impedance analysis (BIA) to estimate fat mass and fat-free mass (Tanita, Tokyo, Japan). Venous blood samples were taken at all scheduled visits for laboratory analyses. Serum CRP was measured at recruitment and week 6 by ELISA (AssayPro, St Charles, MO, USA), and hemoglobin was measured by Hemocue (Angelholm, Sweden) and CD4 count by local central clinical services at recruitment. We did not determine viral loads because of the limited availability of testing at our sites, the high cost and because testing is not routinely available for clinical care in these settings. Furthermore, although providers at clinical sites recorded their diagnoses of suspected opportunistic infections, the diagnostic capacity was very limited and confirmatory testing was often not available, and therefore these data were not included in this analysis.
Sample size
For the main study, we randomized 1876 patients; 61 were subsequently found to have a BMIX18.5 kg/m 2 at the initial clinical visit and excluded, leaving 1815. 17 This number was sufficient to detect, at 5% significance, 90% power and 25% attrition by 12 weeks due to death or loss to followup, differences of 0.18 of s.d. in secondary continuous outcomes measured at 12 weeks. As this study was a planned secondary analysis we did calculate sample size a priori.
Analyses were conducted using Stata 12.1 (College Station, TX, USA) and R-software 3.0.2 (www.r-project.org). Demographics and clinical characteristics of the cohort were presented as percentages or medians with interquartile ranges (IQRs). Participants included in the analysis cohort versus those deceased/lost before 6 weeks after starting ART or without complete laboratory values were compared using the Kruskal-Wallis and χ 2 tests. CRP and body composition measurements were compared pairwise across baseline and 6-week, and baseline and 12-week, time points using the Wilcoxon signed-rank test.
The primary analysis for this paper assessed the relationship between the change in CRP from baseline (pre-ART) to 6 weeks post ART and the change in anthropometric and bioelectric impedance measurements over the same period using linear regression. CRP was log-transformed whereas the anthropometric and BIA outcome measurements remained on a linear scale. Models were adjusted for age, sex, CD4+ count, hemoglobin, treatment arm, country and whether the subject was receiving treatment for tuberculosis before starting ART. Hemoglobin was missing for 8% of cases and was multiply imputed. To account for possible nonlinear associations, continuous variables were modeled using restricted cubic splines with 4 knots. We also adjusted for the number of days between enrollment and ART initiation to reduce bias associated with longer pre-ART periods on supplement.
A second analysis assessed the effect of changes in CRP at 6 weeks with body composition at 12 weeks to determine whether CRP measurements during the LNS intervention predicted longer-term nutritional status after the intervention ended. Using linear regression models, we first tested for a three-way interaction effect between CRP at enrollment, 6 weeks and the intervention arm, but the interaction term was not statistically significant in any of the models (P40.10 for all except calf circumference (P = 0.08)). We then modeled a two-way interaction between CRP values and included the intervention arm as an additive effect. The regression coefficients for baseline and 6-week columns represent the average difference in 12-week body composition for a one-log change around the median baseline and 6-week log-CRP values, respectively. Models were adjusted for age, sex, CD4+ count, hemoglobin, treatment for tuberculosis, site and the number of days between enrollment and ART initiation, and continuous variables were modeled using restricted cubic splines with 4 knots.
The NUSTART trial was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures were approved by the ethics committees of the London School of Hygiene & Tropical Medicine, the University of Zambia and the National Institute for Medical Research, Tanzania. All patients provided written or thumbprint informed consent.
RESULTS
Eight hundred and thirty eight NUSTART participants survived beyond 6 weeks of ART and had serum CRP measurements performed at baseline and 6 weeks post ART. The analysis cohort was 55% female with a median age of 36 years (IQR 30-42), median pre-ART CD4+ T-cell count of 135 cells/μl (IQR 63-225) and median BMI of 16.8 kg/m 2 (IQR 15.9-17.6) ( Table 1) . Participants were equally distributed between the intervention and control arms, with a higher percentage (59%) enrolled in Lusaka (similar to the full cohort). Among those not included in the analysis cohort, 340 had died at 12 weeks, 156 had withdrawn or were lost to follow-up and the remaining 481 alive at 12 weeks either did not have a baseline or 6-week CRP measurement (Table 2 ). In comparison with the analysis cohort, the excluded participants were more likely to be male, younger and had a lower median CD4+ T-cell count and lower median BMI (P o 0.01 for all). Table 3 shows median serum CRP at baseline and 6 weeks of ART, and anthropometric and BIA measurements at baseline and 6 and 12 weeks. Median CRP only decreased from 38.2 mg/l (IQR 8.9-124) to 34.8 mg/l (IQR 12.2-94.5) from baseline to 6 weeks, and was not statistically significant (P = 0.91). The paired change from baseline to 6 weeks of ART for all of the body composition measurements was statistically significant (P o 0.001 for all), and the paired changes from 6 to 12 weeks were also significant (P o 0.01 for all).
The intraindividual changes in serum CRP from baseline to 6 weeks were inversely associated with changes in several of the body composition measurements over the same period (Table 4) . A one-log reduction in CRP was associated with a 0.37 kg/m 2 increase in BMI, a 0.45 cm increase in mid-upper arm circumference, a 0.98 cm increase in waist circumference and 0.58 kg increase in fat-free mass at 6 weeks of ART (P o0.001 for all). Other anthropometric measurements were also inversely related to the change in CRP with the exception of BIA fat mass. These relationships appeared nonlinear. Although greater reductions in log-CRP were generally associated with greater body composition changes, a failure to reduce log-CRP or a rise in log-CRP on ART was generally associated with little change (Figure 1 ). The relationships of CRP at baseline and 6 weeks with body composition at 12 weeks were assessed using linear regression models incorporating baseline and 6-week values, in addition to a two-way interaction term between CRP values (Table 5 ). For the purpose of calculating the effects on body composition, the model for baseline CRP was adjusted to a median log-CRP value of 3.5, and the model for 6-week CRP was adjusted to a median log-CRP of 3.6. A one-log higher CRP at baseline was significantly associated with lower mid-upper arm and waist circumference at 12 weeks. However, a one-log higher 6-week CRP was significantly associated with lower BMI, mid-upper arm, waist, hip and calf circumference and triceps skinfold thickness at 12 weeks. The relationship between 6-week CRP and 12-week BIA fat-free mass approached significance (P = 0.06), whereas there was little Includes participants deceased or lost to follow-up before 6 weeks in addition to those deceased or lost between 6 and 12 weeks, but missing baseline or 6-week CRP measurements.
b P-value refers to comparisons across the four study groups using χ 2 tests for categorical variables and Kruskal-Wallis tests for continuous variables. 
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evidence of an association of CRP with 12-week scapular skinfold thickness and BIA fat mass. Because of the complicated nature of interaction effects, we summarized the statistical models of the combined effect of enrollment and week-6 log-CRP values on the change in 12-week body composition measurements using heat maps (Supplementary Figure 1) . In these figures, deeper shades of blue represent larger increases in body composition measurements at 12 weeks corresponding to a pair of enrollment (x axis) and week-6 (y axis) log-CRP values, whereas deeper shades of violet represent smaller increases (or negative changes in some variables). The change in CRP was associated only with midupper arm, waist and hip circumferences and triceps skinfold thickness (P o0.05), and approached significance for BMI (P = 0.05; P-values refer to the effect of the two-way interaction term (log-CRP at enrollment and week 6) on outcome measurements). In general, larger increases in lean body mass metrics were seen in patients with moderate-to-high baseline CRP and lower 6-week CRP. Model is adjusted to a median baseline log-CRP of 3.5 mg/l. The effect size estimate represents the average difference in 12-week body composition for two individuals with 4.0 versus 3.0 log-CRP at baseline (that is, a one log-CRP increase around the median).
b Model is adjusted to a median week-6 log-CRP of 3.6 mg/l. The effect size estimate represents the average difference in 12-week body composition for two individuals with 4.1 versus 3.1 log-CRP at week 6 (that is, a one log-CRP increase around the median). Inflammation and body composition during early ART G PrayGod et al
DISCUSSION
In this study of undernourished HIV-infected patients starting ART, we found that a failure to reduce excessively high levels of CRP in the early weeks following treatment initiation is associated with failure to accrue lean mass as measured by both anthropometry and BIA. Furthermore, the accumulation of adipose tissue did not appear dependent on CRP reduction, indicating that weight gain in the setting of uncontrolled inflammation may actually represent an unhealthy shift toward adiposity, with potential consequences for metabolic disease in the future. These findings suggest the monitoring of inflammatory biomarkers in undernourished ART patients during the early treatment period, and additional interventions to identify and treat sources of inflammation could improve the nutritional and other health outcomes of this population.
Restoring individuals with advanced HIV disease and malnutrition to health requires both the recovery of effective immune protection and the rebuilding of adequate stores of metabolically active muscle and other lean tissues. 18 Although the initiation of ART by undernourished HIV-infected adults is usually accompanied by weight gain to varying degrees, the composition of the newly deposited tissue is also an important factor in nutritional rehabilitation and the normalization of metabolic processes. Prior studies in diverse HIV-infected populations have found mixed effects of ART on body composition, with some showing no effect on fat and lean mass, and others suggesting that ART may lead to preferential increases in lean or fat mass. 4, [19] [20] [21] However, the factors responsible for this heterogeneous response have not been previously explored in detail.
Our baseline and follow-up levels of CRP were higher than those reported from studies in resource-rich settings and may reflect the combination of untreated viremia, secondary infections related to immunosuppression or local factors (for example, parasites) and enteropathy related to both HIV infection and malnutrition. [6] [7] [8] HIV infection depletes lymphoid cells in the gastrointestinal mucosa integral to defense against bacterial, fungal and parasitic pathogens, and impairs tight junctions between epithelial cells, resulting in altered intestinal integrity and increased translocation of microbes from the intestinal lumen to the circulation. [22] [23] [24] [25] [26] Increased microbial translocation is posited as a major contributor to elevated, chronic inflammation in HIVinfected individuals, likely compounded in the setting of chronic malnutrition because of similar impairments in intestinal mucosal integrity and the adaptive immune response in the gut. [6] [7] [8] 27 Our observation that a higher CRP level is associated with lower lean mass gains may explain the finding in prior nutritional supplementation trials that some patients gained no weight or mainly fat mass during early ART, which has also been reported in patients with similar proinflammatory states such as tuberculosis, severe trauma and cancer, 15, 16, 28 and indicates that across the spectrum of infectious and noninfectious diseases, inflammation may be a key determinant of nutritional depletion and recovery.
Elevated circulating inflammatory cytokines such as tumor necrosis factor-α and interleukin-6 are associated with reduced muscle protein synthesis and deposition, and may stimulate apoptosis in muscle cells precursors, suggesting that the lack of lean mass accumulation in patients with high inflammation may actually be due to failure of protein synthesis rather than excessive protein breakdown. 9, 10 The finding that inflammation and lean mass recovery are closely linked will be important for interpreting findings of future nutritional intervention trials in low-income settings, and it may be the case that any meaningful effects of nutritional interventions on lean mass will depend on first reducing inflammation. Of note, a recent trial in Ethiopia found that persistent HIV-1 viremia, an inflammatory stimulus, at 3 months was associated with preferential fat mass gain, whereas viral suppression was associated with lean mass gain. 21 In the present study, we noted that CRP levels were not closely associated with 6 or 12 weeks post-ART measurements of fat mass, and this may indicate that the accrual of fat mass is driven by other factors independent of inflammation. In higher BMI populations, CRP is positively associated with fat mass. 29 A similar relationship between fat mass and CRP was not observed in our patients; and we hypothesize that any contribution of adipose tissue to circulating inflammatory mediators may have been obscured by the more pronounced effect of advanced malnutrition and HIV infection on systemic inflammation. However, further work is needed to understand the effect of fat mass on the range of plasma inflammation biomarkers in low versus normal and high BMI individuals.
Prior studies in Africa have shown that elevated CRP, interleukin-6 and other markers of systemic inflammation are associated with increased mortality on ART, but there are fewer data on the link between inflammation and health outcomes among patients who remain alive and on treatment. 30 As the capacity of health systems to identify and treat cardiovascular, metabolic and other noncommunicable diseases in HIV patients improves in sub-Saharan Africa, epidemiologic studies are needed to determine how very high levels of inflammation affect longterm health outcomes.
In this study we included approximately half of the patients recruited for the NUSTART trial. Patients excluded because of loss to follow-up or death tended to be those who were more severely malnourished, immunocompromised as judged by CD4 count and those with higher median CRP. Although a higher baseline CRP in the excluded survivors would have potentially resulted in a large reduction in CRP from 0 to 6 weeks, and assuming that the patterns of correlation remained the same, this probably would not have significantly changed the observed associations given that we modeled the relation between CRP and body composition parameters on log scale.
The strength of our study was the prospective design and large sample size that permitted the assessment of longitudinal relationships between CRP and body composition from referral for ART to 6 and 12 weeks post ART. The BIA method that we used was well suited to clinical care in Africa and has been shown to correlate well with more complicated radiographic assessments in healthy patients, but there are fewer data comparing BIA with dual-energy X-ray absorptiometry and other radiographic methods in malnourished, HIV patients. 31 Furthermore, our study could not assess the long-term implications of early changes in body composition on ART. We observed a 0.37 kg/m 2 rise in BMI at 6 weeks in patients with a one-log CRP reduction over the same period, representing an ∼ 2-2.5% BMI increase (depending on the baseline BMI value). Prior studies have shown modest early increases in BMI are clinically important for long-term survival, but additional studies are warranted to understand how body composition, inflammation and other nutritional factors interact to influence health outcomes. 32 Lastly, although patients in the NUSTART study received LNS for the first 6 weeks of ART, any added benefit would likely have disappeared a few weeks after starting treatment as patients regained appetite and started consuming nutritionally diverse food.
CONCLUSIONS
In conclusion, among HIV-infected adult patients, reductions in CRP over the first 6 weeks of ART were associated with higher lean body mass gains; and patients with lower CRP at 6 weeks continued to have greater lean mass up to 12 weeks. Promoting lean body mass gains in malnourished HIV patients starting ART is important for nutritional rehabilitation and may affect long-term survival and chronic disease risk. Future trials should consider interventions addressing both nutritional recovery and inflammation to elucidate mechanisms and optimize outcomes in malnourished patients. Finally, further studies on the effect of persistent high level of inflammation as well as fat mass gains on long-term chronic disease risk, including diabetes mellitus and cardiovascular conditions, are needed in sub-Saharan Africa.
